中华中医药学刊

雷公藤红素对PTEN介导PI3K/PKB信号通路改善特发性肺纤维化的实验研究

PDF下载

陈红红 ¹ , 吴珂 ¹ , 林龙 ¹ , 莫名月 ¹ , 朱裕林 ¹ , 李熠桓 ¹ , 陈依萍 ¹ , 刘婉婷 ¹ , 张嘉妍 ¹ , 吴雅逸 ¹ , 付跃峰 ²

中华中医药学刊 | 国家项目点击 2026,44(8): 91-96

收起

中华中医药学刊 |国家项目点击 2026 , 44 (8) : 91 -96

雷公藤红素对PTEN介导PI3K/PKB信号通路改善特发性肺纤维化的实验研究

全屏

陈红红¹, 吴珂¹, 林龙¹, 莫名月¹, 朱裕林¹, 李熠桓¹, 陈依萍¹, 刘婉婷¹, 张嘉妍¹, 吴雅逸¹, 付跃峰²

作者信息

^1.广州南方学院云康医学与健康学院，广东　广州　510900

^2.北京中医药大学东直门医院，北京　100700

通讯作者:

付跃峰（1985-），男，河南登封人，副主任医师，硕士研究生导师，硕士，研究方向：中西医结合防治急危重症。E-mail：272167303@qq.com。

作者简介:

陈红红（1989-），女，广东韶关人，讲师，硕士，研究方向：呼吸系统疾病机制。

Experimental Study of Celastrol Ameliorating Idiopathic Pulmonary Fibrosis by PTEN-mediated PI3K/PKB Signaling Pathway

Honghong CHEN¹, Ke WU¹, Long LIN¹, Mingyue MO¹, Yulin ZHU¹, Yihuan LI¹, Yiping CHEN¹, Wanting LIU¹, Jiayan ZHANG¹, Yayi WU¹, Yuefeng FU²

Affiliations

^1.Yunkang School of Medicine and Health, Nanfang College Guangzhou, Guangzhou 510900, Guangzhou, China

^2.Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China

出版时间: 2026-08-10 doi: 10.13193/j.issn.1673-7717.2026.08.020

文章导航

摘要

收起

目的

观察雷公藤红素对磷酸酯酶与张力蛋白同源物（Phosphatase and tensin homolog，PTEN）介导磷脂酰肌醇3-激酶（Phosphatidyl inositol 3-kinase，PI3K）/蛋白激酶B（Protein kinase B，PKB）信号通路在特发性肺纤维化（Idiopathic pulmonary fibrosis，IPF）模型小鼠中的作用及机制。

方法

C57BL/6小鼠随机区组平均分为4组，每组10只，包括正常组、模型组、雷公藤红素（1 mg·kg^-1·d^-1）组、吡非尼酮组（50 mg·kg^-1·d^-1）。以气管滴注博来霉素（Bleomycin，BLM）的方法制备IPF小鼠模型。造模成功后，各观察组灌胃给药，正常组灌胃等量生理盐水，连续给药28 d，末次给药后第2天取材。HE常规病理染色观察肺组织病理变化，Masson特殊染色观察小鼠肺间质及支气管周围胶原沉积。免疫组化（Immunohistochemistry，IHC）检测PTEN以及I型胶原在肺组织中的原位表达，实时荧光定量PCR（Quantitative real-time PCR，qRT-PCR）检测肺组织中PTEN、PI3K、PKB及白细胞介素（interleukin，IL）-17βmRNA表达。

结果

与正常组相比，模型组肺间质I型胶原蛋白的表达显著增强（P<0.05），PTEN蛋白的表达明显减弱（P<0.05）；肺组织匀浆PI3K、PKB及IL-17β mRNA表达均显著增强（P<0.05），PTEN mRNA表达显著减弱（P<0.05）。与模型组相比，雷公藤红素及吡非尼酮组肺间质I型胶原蛋白的表达明显减弱（P<0.05），PTEN蛋白的表达明显增强（P<0.05）；肺组织匀浆PI3K、PKB及IL-17β mRNA表达显著减弱（P<0.05），PTEN mRNA表达显著增强（P<0.05）。

结论

雷公藤红素能有效抑制肺间质的结构破坏，减轻肺纤维化。其机制可能通过激活PTEN，并协调性抑制PI3K/PKB的表达，降低炎症反应，阻止肺间质胶原的沉积。

关键词

特发性肺纤维化 / 雷公藤红素 / 磷酸酯酶与张力蛋白同源物 / 磷脂酰肌醇3-激酶 / 蛋白激酶B / I型胶原

Abstract

收起

Objective

To observe the effect and mechanism of Celastrol extract on the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling pathway mediated by phosphatase and tensin homolog (PTEN) in idiopathic pulmonary fibrosis (IPF) model mice.

Methods

C57BL/6 mice were randomly divided into 4 groups with an average of 10 mice in each group, including normal group, model group, celastrol (1 mg·kg^-1·d^-1) group and pirfenidone (50 mg·kg^-1·d^-1) group. The IPF mouse model was established by intratracheal instillation of bleomycin (BLM). After successful modeling, each observation group was orally administered (ig), while the normal group was orally administered an equal amount of physiological saline for 28 consecutive days. The samples were taken out on the second day after the last administration. The pathological changes in lung tissue were observed through routine HE staining and collagen deposition in mouse lung interstitium and peribronchial tissue were observed through Masson special staining. Immunohistochemistry (IHC) method was used to detect the in situ expressions of PTEN and type I collagen in lung tissue, while quantitative real-time PCR (qRT-PCR)) was used to detect the mRNA expressions of PTEN, PI3K, PKB and interleukin (IL)-17β in lung tissue.

Results

Compared with that of the normal group, the expression of type I collagen in the lung interstitium was significantly increased in the model group (P<0.05). The expressions of PI3K, PKB and IL-17β mRNA in lung tissue were significantly increased (P<0.05), and the expression of PTEN mRNA was significantly decreased (P<0.05). Compared with the model group, the celastrol and pirfenidone groups had a significant reduction in the expression of type I collagen in the lung tissue (P<0.05) and the expression of PTEN protein was significantly enhanced (P<0.05). The expressions of PI3K, PKB and IL-17β mRNA in lung tissue were significantly decreased (P<0.05), and the expression of PTEN mRNA was significantly increased (P<0.05).

Conclusion

Celastrol extract can effectively inhibit the structural damage of lung interstitium and alleviate pulmonary fibrosis. The mechanism may be achieved by activating PTEN and coordinating the inhibition of PI3K/PKB expression, reducing inflammatory response and preventing the deposition of pulmonary interstitial collagen.

Key words

idiopathic pulmonary fibrosis / Celastrol / phosphatase and tensin homolog (PTEN) / phosphatidylinositol 3-kinase (PI3K) / protein kinase B (PKB) / type I collagen

引用本文

陈红红, 吴珂, 林龙, 莫名月, 朱裕林, 李熠桓, 陈依萍, 刘婉婷, 张嘉妍, 吴雅逸, 付跃峰. 雷公藤红素对PTEN介导PI3K/PKB信号通路改善特发性肺纤维化的实验研究. 中华中医药学刊, 2026 , 44 (8) : 91 -96 . DOI: 10.13193/j.issn.1673-7717.2026.08.020

Honghong CHEN, Ke WU, Long LIN, Mingyue MO, Yulin ZHU, Yihuan LI, Yiping CHEN, Wanting LIU, Jiayan ZHANG, Yayi WU, Yuefeng FU. Experimental Study of Celastrol Ameliorating Idiopathic Pulmonary Fibrosis by PTEN-mediated PI3K/PKB Signaling Pathway[J]. Chinese Archives of Traditional Chinese Medicine, 2026 , 44 (8) : 91 -96 . DOI: 10.13193/j.issn.1673-7717.2026.08.020

基金

收起

国家自然科学基金青年科学基金项目(82000355)
中央高水平中医医院临床科研业务费项目(CZ015)
中华中医药学会青年求实项目(2021-QNQS-001)
中华中医药学会雏鹰计划-第一批中医临床青年人才项目(CYJH2024008)
广东省自然科学基金项目(2018A030310016)
广东省普通高校特色创新类科研项目(2018KTSCX321)
广州市科技计划项目(202102080037)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

尹成胜, 徐作军. 间质性肺疾病研究进展[J]. 中国实用内科杂志, 2024, 44(6): 441-445, 456.

[2]

GLASS D S, GROSSFELD D, RENNA H A, et al. Idiopathic pulmonary fibrosis: Current and future treatment[J]. Clinical Respiratory J, 2022, 16(2): 84-96.

[3]

HEUKELS P, MOOR C C, VON DER THÜSEN J H, et al. Inflammation and immunity in IPF pathogenesis and treatment[J]. Respir Med, 2019, 147: 79-91.

[4]

HE Y, SUN M M, ZHANG G G, et al. Targeting PI3K/Akt signal transduction for cancer therapy[J]. Sig Transduct Target Ther, 2021, 6: 425.

[5]

YANG D P, CHEN X, WANG J J, et al. Dysregulated lung commensal bacteria drive interleukin-17B production to promote pulmonary fibrosis through their outer membrane vesicles[J]. Immunity, 2019, 50(3): 692-706.

[6]

SHE Y X, YU Q Y, TANG X X. Role of interleukins in the pathogenesis of pulmonary fibrosis[J]. Cell Death Discov, 2021, 7: 52.

[7]

NIE Y J, WU S H, XUAN Y H, et al. Role of IL-17 family cytokines in the progression of IPF from inflammation to fibrosis[J]. Military Med Res, 2022, 9: 21.

[8]

RITZMANN F, LUNDING L P, BALS R, et al. IL-17 cytokines and chronic lung diseases[J]. Cells, 2022, 11(14): 2132.

[9]

LIU A, ZHU Y Y, CHEN W P, et al. PTEN dual lipid-and protein-phosphatase function in tumor progression[J]. Cancers, 2022, 14(15): 3666.

[10]

TU M J, WEI T, JIA Y F, et al. Molecular mechanisms of alveolar epithelial cell senescence and idiopathic pulmonary fibrosis: a narrative review[J]. J Thorac Dis, 2023, 15(1): 186-203.

[11]

CARNERO A, BLANCO-APARICIO C, RENNER O, et al. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications[J]. Curr Cancer Drug Targets, 2008, 8(3): 187-198.

[12]

MARAT A L, HAUCKE V. Phosphatidylinositol 3-phosphates—at the interface between cell signalling and membrane traffic[J]. EMBO J, 2016, 35(6): 561-579.

[13]

金泓宇, 王丹丹, 宋昕怡, 等. 雷公藤红素通过调控Ezrin的活化改善特应性皮炎[J]. 中国药理学通报, 2024, 40(10): 1921-1930.

[14]

池宏宇, 姚雪敏, 张国鑫, 等. 肥胖与抑郁共病小鼠模型建立及在雷公藤红素药效药理研究中的应用[J]. 中国实验方剂学杂志, 2022, 28(14): 81-91.

[15]

荆紫琪, 王雪, 闫天月, 等. 靶向叶酸受体和线粒体的载雷公藤红素PAMAM纳米递药系统构建及体外抗炎作用[J]. 药学学报, 2023, 58(3): 550-559.

[16]

HUANG E Y, PENG N, XIAO F, et al. The roles of immune cells in the pathogenesis of fibrosis[J]. Int J Mol Sci, 2020, 21(15): 5203.

[17]

FAN J W, REN M, CHEN W W, et al. Celastrol relieves myocardial infarction-induced cardiac fibrosis by inhibiting NLRP3 inflammasomesinrats[J]. IntImmunopharmacol, 2023, 121: 110511.

[18]

MECOZZI L, MAMBRINI M, RUSCITTI F, et al. In-vivo lung fibrosis staging in a bleomycin-mouse model: a new micro-CT guided densitometric approach[J]. Sci Rep, 2020, 10: 18735.

[19]

GUL A, YANG F Y, XIE C, et al. Pulmonary fibrosis model of mice induced by different administration methods of bleomycin[J]. BMC Pulm Med, 2023, 23(1): 91.

[20]

RUWANPURA S M, THOMAS B J, BARDIN P G. Pirfenidone: molecular mechanisms and potential clinical applications in lung disease[J]. Am J Respir Cell Mol Biol, 2020, 62(4): 413-422.

[21]

TEPEDE A, YOGARATNAM D. Nintedanib for idiopathic pulmonary fibrosis[J]. J Pharm Pract, 2019, 32(2): 199-206.

[22]

LI T H, GAO X J, JIA R, et al. Astragaloside IV inhibits idiopathic pulmonary fibrosis through activation ofautophagy by miR-21-mediated PTEN/PI3K/AKT/mTOR pathway[J]. Cell Mol Biol (Noisy-le-grand), 2024, 70(2): 128-136.

[23]

KOLB P, UPAGUPTA C, VIERHOUT M, et al. The importance of interventional timing in the bleomycin model of pulmonary fibrosis[J]. Eur Respir J, 2020, 55(6): 1901105.

[24]

KOUDSTAAL T, WIJSENBEEK M S. Idiopathic pulmonary fibrosis[J]. La Presse Médicale, 2023, 52(3): 104166.

[25]

LIU G, PHILP A M, CORTE T, et al. Therapeutic targets in lung tissue remodelling and fibrosis[J]. Pharmacol Ther, 2021, 225: 107839.

[26]

MERCER P F, WOODCOCK H V, ELEY J D, et al. Exploration of a potent PI₃ kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF[J]. Thorax, 2016, 71(8): 701-711.

[27]

YANG J, NIE J, MA X L, et al. Targeting PI3K in cancer: mechanisms and advances in clinical trials[J]. Mol Cancer, 2019, 18(1): 26.

[28]

WANG J C, HU K L, CAI X Y, et al. Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis[J]. Acta Pharm Sin B, 2022, 12(1): 18-32.

[29]

HADDADI N, LIN Y G, TRAVIS G, et al. PTEN/PTENP1: ‘Regulating the regulator of RTK-dependent PI3K/Akt signalling’, new targets for cancer therapy[J]. Mol Cancer, 2018, 17(1): 37.

[30]

TIAN Y Q, LI H, QIU T, et al. Loss of PTEN induces lung fibrosis via alveolar epithelial cell senescence depending on NF-κB activation[J]. Aging Cell, 2019, 18: e12858.

[31]

NADERALI E, KHAKI A A, RAD J S, et al. Regulation and modulation of PTEN activity[J]. Mol Biol Rep, 2018, 45(6): 2869-2881.

[32]

CAI B R, YANG L, DO JUNG Y, et al. PTEN: an emerging potential target for therapeutic intervention in respiratory diseases[J]. Oxid Med Cell Longev, 2022, 2022: 4512503.

[33]

MARGARIA J P, MORETTA L, ALVES-FILHO J C, et al. PI3K signaling in mechanisms and treatments of pulmonary fibrosis following sepsis and acute lung injury[J]. Biomedicines, 2022, 10(4): 756.

2026年第44卷第8期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.13193/j.issn.1673-7717.2026.08.020

首发时间：2026-10-20
出版时间：2026-08-10

补充材料

相关文章

文章信息

作者

出版历史

基金

国家自然科学基金青年科学基金项目(82000355)

中央高水平中医医院临床科研业务费项目(CZ015)

中华中医药学会青年求实项目(2021-QNQS-001)

中华中医药学会雏鹰计划-第一批中医临床青年人才项目(CYJH2024008)

广东省自然科学基金项目(2018A030310016)

广东省普通高校特色创新类科研项目(2018KTSCX321)

广州市科技计划项目(202102080037)

作者信息

^1.广州南方学院云康医学与健康学院，广东　广州　510900

^2.北京中医药大学东直门医院，北京　100700

通讯作者:

付跃峰（1985-），男，河南登封人，副主任医师，硕士研究生导师，硕士，研究方向：中西医结合防治急危重症。E-mail：272167303@qq.com。

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zhzyyxk/CN/10.13193/j.issn.1673-7717.2026.08.020

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT